Nicole Goh,1 Christopher P Denton,2 David A Lynch,3 Toby M Maher,4 Vanessa Smith,5 Antje Prasse,6 Vincent Cottin,7 Robert Spiera,8 Christian Stock,9 Martina Gahlemann,10 Margarida Alves,11 Athol U Wells12 on behalf of the SENSCIS trial investigators
1Respiratory and Sleep Medicine, Austin Health, and Institute for Breathing and Sleep, Melbourne, Victoria, Australia; 2University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, UK; 3Department of Radiology, National Jewish Health, Denver, Colorado, USA; 4National Heart and Lung Institute, Imperial College London and National Institute for Health Research Clinical Research Facility, Royal Brompton Hospital, London, UK; 5Department of Rheumatology, Ghent University Hospital; Department of Internal Medicine, Ghent University; Unit for Molecular Immunology and Inflammation, VIB Inflammation Research Center (IRC), Ghent, Belgium; 6MHH Hannover Medical School, Department of Respiratory Medicine, Hannover, Germany; 7National Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, Hospices Civils de Lyon, Claude Bernard University Lyon 1, Lyon, France; 8Division of Rheumatology, Hospital for Special Surgery, New York, New York, USA; 9Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany; 10Boehringer Ingelheim (Schweiz) GmbH, Basel, Switzerland; 11Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany; 12National Institute for Health Research Respiratory Biomedical Research Unit, Royal Brompton and Harefield NHS Foundation Trust, and National Heart and Lung Institute, Imperial College, London, UK
Introduction
- Interstitial lung disease (ILD) is the leading cause of death in patients with systemic sclerosis (SSc).1
- In the SENSCIS trial in subjects with SSc-ILD, nintedanib reduced the rate of decline in forced vital capacity (FVC) (mL/year) over 52 weeks by 44% versus placebo.2
- Previous studies have suggested that patients with SSc-ILD who have more extensive fibrotic ILD on a high-resolution computed tomography (HRCT) scan have a worse prognosis than patients with less extensive disease.3,4